4 stories mentioning PVLAUpdated 10d ago
Every FINWIRES story that references PVLA, newest first.
Palvella Therapeutics (PVLA) reported Q2 net loss Tuesday of $1.52 per diluted share, widening from a loss of $0.86 a year earlier.Analysts polled by FactSet expected a $1.07 loss per share.No revenue was reported for the quarter, as expected.The company had $250.6 million in cash, cash equivalents, and short-term investments as of June 30, 2026.Price: $135.30, Change: $-5.48, Percent Change: -3.89%
Palvella Therapeutics (PVLA) said Wednesday the United States Patent and Trademark Office has issued a patent, exclusively licensed from Yale University, supporting Palvella's QTORIN pitavastatin program for porokeratosis, including disseminated superficial actinic porokeratosis.QTORIN pitavastatin is an investigational topical therapy designed to enable pathogenesis-directed inhibition of the mevalonate pathway on-target and directly within affected skin tissue in porokeratosis, according to the company.The patent covers topical administration of HMG-CoA reductase inhibitors, including pitavastatin, for the treatment of porokeratosis, providing protection into 2043 for this pathogenesis-directed treatment approach, the company said.Palvella said it has also filed an additional patent application covering the QTORIN-derived formulation of pitavastatin and other statins and methods of use.Price: $116.72, Change: $-0.88, Percent Change: -0.74%
Palvella Therapeutics (PVLA) stock was down more than 7% early Thursday after the company reported a Q1 net loss of $1.20 per diluted share, widening from $0.74 a year earlier.Analysts polled by FactSet expected a $0.97 loss per share.No revenue was reported for the quarter, as expected.Price: $120.99, Change: $-9.18, Percent Change: -7.05%
